nuv-422
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 4, 2020 (NCT04541225)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cyclin-dependent kinase 6INHIBITOR
CDK6 inhibitor
- CDK2/CDK4INHIBITOR
CDK2/CDK4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05191017 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2022 | Nuvation Bio Inc. |
| NCT05191004 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2022 | Nuvation Bio Inc. |
| NCT04541225 | Phase 1/Phase 2 (Phase 2) | Nov 4, 2020 | Nuvation Bio Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nuvation Bio Inc. | For profit | 3 | 3 | 1 | 2020 |
1 organizations
Page 1 / 1